J9029 HCPCS code: Intravesical instillation, nadofaragene firadenovec-vncg, per therapeutic dose
J9029 is the HCPCS Level II code for intravesical instillation, nadofaragene firadenovec-vncg, per therapeutic dose. In 2024 Medicare paid an average of $33,976.08 per service for J9029 across 508 services. Its Medicare coverage code is C (Carrier judgment): Coverage is decided by the Medicare contractor (MAC) case by case. The NCCI unit limit is 1 per day on outpatient hospital claims. Medicare volume rose 2319% from 2023 to 2024 (21 to 508 services). In 2024, about 177 clinicians billed Medicare for J9029 for 230 beneficiaries; Texas, Arizona, Georgia accounted for 73% of services.
Code details
| Field | Value |
|---|---|
| Section | J codes — Drugs administered other than oral method |
| Coverage code | C — Carrier judgment |
| Pricing indicator | 51 — Drug or biological (priced per ASP/average sales price rules) |
| BETOS category | O1D — Chemotherapy |
| Added | 2023-07-01 |
| Last action effective | 2024-01-01 |
Who bills J9029 (2024)
| Measure | Value |
|---|---|
| Clinicians billing (by place of service) | 177 |
| Medicare beneficiaries | 230 |
| States with claims | 6 |
| Share of services in top 3 states (Texas, Arizona, Georgia) | 73% |
Counts only. Supplier and clinician names, contact lists and state-by-state detail are in Caduvo.
Medicare utilization for J9029, 2023–2024
| Year | Services | Beneficiaries | Avg. allowed | Avg. paid |
|---|---|---|---|---|
| 2023 | 21 | 17 | $53,834.17 | $42,892.27 |
| 2024 | 508 | 230 | $42,644.92 | $33,976.08 |
States with the most J9029 services (2024)
| State | Services | Avg. paid |
|---|---|---|
| Texas | 107 | $15,257.84 |
| Arizona | 58 | $49,542.83 |
| Florida | 33 | $49,583.26 |
| Georgia | 33 | $49,004.92 |
| Tennessee | 21 | $49,604.94 |
NCCI unit limits (MUE)
| Claim type | Max units per day | Rationale |
|---|---|---|
| outpatient hospital claims | 1 | Prescribing Information |
| practitioner claims | 1 | Prescribing Information |
What changed for J9029
- 2023-07-01: J9029 added to HCPCS Level II
- Next scheduled CMS quarterly update (HCPCS and DMEPOS fee schedule): 2027-01-01
Frequently asked questions
What is HCPCS code J9029?
J9029 is the HCPCS Level II code for intravesical instillation, nadofaragene firadenovec-vncg, per therapeutic dose. Short descriptor: "Instill adstiladrin, tx dose".
How much does Medicare pay for J9029?
In 2024, the average Medicare payment was $33,976.08 per service (average allowed $42,644.92).
Does Medicare cover J9029?
Coverage code C — Carrier judgment. Coverage is decided by the Medicare contractor (MAC) case by case.
How many units of J9029 can be billed per day?
1 on outpatient hospital claims; 1 on practitioner claims (NCCI medically unlikely edits).
Related J90 codes
- J9000 — Injection, doxorubicin hydrochloride, 10 mg
- J9003 — Leuprolide injectable (camcevi etm), 1 mg
- J9010 — Injection, alemtuzumab, 10 mg
- J9011 — Injection, datopotamab deruxtecan-dlnk, 1 mg
- J9015 — Injection, aldesleukin, per single use vial
- J9017 — Injection, arsenic trioxide, 1 mg
- J9019 — Injection, asparaginase (erwinaze), 1,000 iu
- J9020 — Injection, asparaginase, not otherwise specified, 10,000 units
- J9021 — Injection, asparaginase, recombinant, (rylaze), 0.1 mg
- J9022 — Injection, atezolizumab, 10 mg
- J9023 — Injection, avelumab, 10 mg
- J9024 — Injection, atezolizumab, 5 mg and hyaluronidase-tqjs
Building a device that would bill under a code like this? Caduvo matches a device description to HCPCS/CPT codes, Medicare coverage and payment, and the FDA pathway in one report.
Next steps
- Run a reimbursement report for a device billed under J9029
- Watch J9029 for fee, coverage and descriptor changes
- Build a full Medicare revenue model for J9029
Sources: CMS HCPCS Level II release October 2026; CMS DMEPOS fee schedule; CMS NCCI MUE tables; CMS Medicare utilization (physician and DME supplier files); CMS Medicare Coverage Database articles. Fees are Medicare allowables, not commercial rates. Not billing or legal advice.